Lupin Launches Tetrabenazine Tab – CORPORATE ETHOS

Lupin Launches Tetrabenazine Tab

By: | November 21, 2018

Nov 21: Pharma major Lupin Ltd on Wednesday announced the launch of its Tetrabenazine Tablets, 12.5 mg and 25 mg, having received an approval from the United States Food and Drug Administration (FDA) earlier.

According to Lupin, its Tetrabenazine Tablets, 12.5 mg and 25 mg are the generic equivalent of Valeant Pharmaceuticals North America, LLC’s Xenazine tablets. It is indicated for the treatment of chorea associated with Huntington’s disease, the company said.

Xenazine tablets had annual sales of $153 million in the US (IQVIA MAT September 2018).